Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
94.81
-0.09 (-0.09%)
At close: Oct 29, 2025, 4:00 PM EDT
94.81
0.00 (0.00%)
After-hours: Oct 29, 2025, 4:10 PM EDT
Merus Employees
As of December 31, 2024, Merus had 321 total employees, including 260 full-time and 61 part-time employees. The number of employees increased by 92 or 40.17% compared to the previous year.
Employees
321
Change (1Y)
92
Growth (1Y)
40.17%
Revenue / Employee
$175,165
Profits / Employee
-$1,200,997
Market Cap
7.19B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 321 | 92 | 40.17% |
| Dec 31, 2023 | 229 | 8 | 3.62% |
| Dec 31, 2022 | 221 | 80 | 56.74% |
| Dec 31, 2020 | 141 | 9 | 6.82% |
| Dec 31, 2019 | 132 | 34 | 34.69% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MRUS News
- 23 hours ago - 3 Investable Laggards In An Overbought Market - Seeking Alpha
- 5 days ago - Merus' Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety - GlobeNewsWire
- 6 days ago - Merus Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS - Business Wire
- 8 days ago - Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V. - GlobeNewsWire
- 15 days ago - Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 16 days ago - Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - GlobeNewsWire
- 4 weeks ago - MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS - Business Wire
- 4 weeks ago - Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough - Benzinga